Evidence map›Paper›PMID 40927306›Full record

ReviewJournal of immunotherapy and precision oncology2025

Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.

AbdulAziz AlJassim, Aladdin Kanbour, Fathi Azribi, Muath AlNassar, Riadh Mohsen, Sahar Dawod, Selvaraj Giri, Michael Nasr Kamal, Ali AlJabban, Layth Mula-Hussain and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of immunotherapy and precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

AbdulAziz AlJassimKuwait Cancer Control Center, Kuwait City, Kuwait.ORCID https://orcid.org/0000-0002-6094-1553
Aladdin KanbourHamad Medical Corporation, Doha, Qatar.
Fathi AzribiAmerican Hospital, Dubai, UAE.
Muath AlNassarKuwait Cancer Control Center, Kuwait City, Kuwait.
Riadh MohsenHamad Medical Corporation, Doha, Qatar.
Sahar DawodRoyal Hospital, Muscat, Oman.
Selvaraj GiriTawam Hospital, AlAin, UAE.
Michael Nasr KamalMedical Affairs, Gulf Region, Pfizer Inc., Dubai, UAE.
Ali AlJabbanMedical Affairs, Gulf Region, Pfizer Inc., Dubai, UAE.
Layth Mula-HussainRadiation Oncology, Faculty of Medicine, University of British Columbia, BC, Canada.
Bader AlshamsanDepartment of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia.ORCID https://orcid.org/0000-0003-2462-0581
Emad AnwarTawam Hospital, AlAin, UAE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of

Indexed as

Gulflung cancer treatmentMENAmutationnon–small cell lung cancerNSCLC

Identifiers

PMID40927306
PMCPMC12416486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.